Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia

results of a phase 2 study

Guillermo Garcia-Manero, Yasmin Abaza, Koichi Takahashi, Bruno C. Medeiros, Martha Arellano, Samer K. Khaled, Mrinal Patnaik, Olatoyosi Odenike, Hamid Sayar, Mohan Tummala, Prapti Patel, Lori J Maness-Harris, Robert Stuart, Elie Traer, Kasra Karamlou, Abdulraheem Yacoub, Richard Ghalie, Ruben Giorgino, Ehab Atallah

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Pracinostat, a potent oral pan-histone deacetylase inhibitor with modest single-agent activity in acute myeloid leukemia (AML), has shown synergistic antitumor activity when combined with azacitidine. This single-group, multicenter phase 2 study assessed the safety and efficacy of pracinostat combined with azacitidine in patients who were at least 65 years old with newly diagnosed AML and who were ineligible for standard induction chemotherapy. Patients received pracinostat 60 mg/d, 3 d/wk, for 3 consecutive weeks, plus azacitidine 75 mg/m2 daily for 7 days in a 28-day cycle. Primary endpoints were complete remission (CR), CR with incomplete count recovery (CRi), and morphologic leukemia-free state (MLFS) rates of the combination. Secondary endpoints included safety, progression-free survival (PFS), and overall survival (OS) of the regimen. Fifty patients (33 de novo, 12 secondary, and 5 therapy-related AML) were enrolled. Twenty-six patients (52%) achieved the primary endpoint of CR (42%), CRi (4%), and MLFS (6%). Median OS and PFS were 19.1 months (95% confidence interval [CI], 10-26.5 months) and 12.6 months (95% CI, 10-17.7 months), respectively, with a 1-year OS rate of 62%. Forty-three patients (86%) experienced at least 1 grade 3 or worse treatment-emergent adverse event with the combination, with infections (52%), thrombocytopenia (46%), and febrile neutropenia (44%) reported as the most common toxicities. The 30- and 60-day all-cause mortality rates were 2% and 10%, respectively. DNA sequencing revealed somatic mutations at baseline, and clearance rates correlated with response to treatment. Pracinostat plus azacitidine is a well-tolerated and active regimen in the frontline treatment of older patients with AML unfit for intensive therapy. A larger controlled trial is ongoing. This trial was registered at www.clinicaltrials.gov as #NCT01912274.

Original languageEnglish (US)
Pages (from-to)508-518
Number of pages11
JournalBlood advances
Volume3
Issue number4
DOIs
StatePublished - Feb 26 2019

Fingerprint

Azacitidine
Acute Myeloid Leukemia
Disease-Free Survival
Leukemia
Confidence Intervals
Therapeutics
Safety
Febrile Neutropenia
Induction Chemotherapy
Histone Deacetylase Inhibitors
Survival
DNA Sequence Analysis
Thrombocytopenia
SB939 compound
Survival Rate
Mutation
Mortality
Infection

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Garcia-Manero, G., Abaza, Y., Takahashi, K., Medeiros, B. C., Arellano, M., Khaled, S. K., ... Atallah, E. (2019). Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study. Blood advances, 3(4), 508-518. https://doi.org/10.1182/bloodadvances.2018027409

Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia : results of a phase 2 study. / Garcia-Manero, Guillermo; Abaza, Yasmin; Takahashi, Koichi; Medeiros, Bruno C.; Arellano, Martha; Khaled, Samer K.; Patnaik, Mrinal; Odenike, Olatoyosi; Sayar, Hamid; Tummala, Mohan; Patel, Prapti; Maness-Harris, Lori J; Stuart, Robert; Traer, Elie; Karamlou, Kasra; Yacoub, Abdulraheem; Ghalie, Richard; Giorgino, Ruben; Atallah, Ehab.

In: Blood advances, Vol. 3, No. 4, 26.02.2019, p. 508-518.

Research output: Contribution to journalArticle

Garcia-Manero, G, Abaza, Y, Takahashi, K, Medeiros, BC, Arellano, M, Khaled, SK, Patnaik, M, Odenike, O, Sayar, H, Tummala, M, Patel, P, Maness-Harris, LJ, Stuart, R, Traer, E, Karamlou, K, Yacoub, A, Ghalie, R, Giorgino, R & Atallah, E 2019, 'Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study', Blood advances, vol. 3, no. 4, pp. 508-518. https://doi.org/10.1182/bloodadvances.2018027409
Garcia-Manero, Guillermo ; Abaza, Yasmin ; Takahashi, Koichi ; Medeiros, Bruno C. ; Arellano, Martha ; Khaled, Samer K. ; Patnaik, Mrinal ; Odenike, Olatoyosi ; Sayar, Hamid ; Tummala, Mohan ; Patel, Prapti ; Maness-Harris, Lori J ; Stuart, Robert ; Traer, Elie ; Karamlou, Kasra ; Yacoub, Abdulraheem ; Ghalie, Richard ; Giorgino, Ruben ; Atallah, Ehab. / Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia : results of a phase 2 study. In: Blood advances. 2019 ; Vol. 3, No. 4. pp. 508-518.
@article{e853deeee8044099a14eff6283081dc6,
title = "Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study",
abstract = "Pracinostat, a potent oral pan-histone deacetylase inhibitor with modest single-agent activity in acute myeloid leukemia (AML), has shown synergistic antitumor activity when combined with azacitidine. This single-group, multicenter phase 2 study assessed the safety and efficacy of pracinostat combined with azacitidine in patients who were at least 65 years old with newly diagnosed AML and who were ineligible for standard induction chemotherapy. Patients received pracinostat 60 mg/d, 3 d/wk, for 3 consecutive weeks, plus azacitidine 75 mg/m2 daily for 7 days in a 28-day cycle. Primary endpoints were complete remission (CR), CR with incomplete count recovery (CRi), and morphologic leukemia-free state (MLFS) rates of the combination. Secondary endpoints included safety, progression-free survival (PFS), and overall survival (OS) of the regimen. Fifty patients (33 de novo, 12 secondary, and 5 therapy-related AML) were enrolled. Twenty-six patients (52{\%}) achieved the primary endpoint of CR (42{\%}), CRi (4{\%}), and MLFS (6{\%}). Median OS and PFS were 19.1 months (95{\%} confidence interval [CI], 10-26.5 months) and 12.6 months (95{\%} CI, 10-17.7 months), respectively, with a 1-year OS rate of 62{\%}. Forty-three patients (86{\%}) experienced at least 1 grade 3 or worse treatment-emergent adverse event with the combination, with infections (52{\%}), thrombocytopenia (46{\%}), and febrile neutropenia (44{\%}) reported as the most common toxicities. The 30- and 60-day all-cause mortality rates were 2{\%} and 10{\%}, respectively. DNA sequencing revealed somatic mutations at baseline, and clearance rates correlated with response to treatment. Pracinostat plus azacitidine is a well-tolerated and active regimen in the frontline treatment of older patients with AML unfit for intensive therapy. A larger controlled trial is ongoing. This trial was registered at www.clinicaltrials.gov as #NCT01912274.",
author = "Guillermo Garcia-Manero and Yasmin Abaza and Koichi Takahashi and Medeiros, {Bruno C.} and Martha Arellano and Khaled, {Samer K.} and Mrinal Patnaik and Olatoyosi Odenike and Hamid Sayar and Mohan Tummala and Prapti Patel and Maness-Harris, {Lori J} and Robert Stuart and Elie Traer and Kasra Karamlou and Abdulraheem Yacoub and Richard Ghalie and Ruben Giorgino and Ehab Atallah",
year = "2019",
month = "2",
day = "26",
doi = "10.1182/bloodadvances.2018027409",
language = "English (US)",
volume = "3",
pages = "508--518",
journal = "Blood advances",
issn = "2473-9529",
publisher = "American Society of Hematology",
number = "4",

}

TY - JOUR

T1 - Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia

T2 - results of a phase 2 study

AU - Garcia-Manero, Guillermo

AU - Abaza, Yasmin

AU - Takahashi, Koichi

AU - Medeiros, Bruno C.

AU - Arellano, Martha

AU - Khaled, Samer K.

AU - Patnaik, Mrinal

AU - Odenike, Olatoyosi

AU - Sayar, Hamid

AU - Tummala, Mohan

AU - Patel, Prapti

AU - Maness-Harris, Lori J

AU - Stuart, Robert

AU - Traer, Elie

AU - Karamlou, Kasra

AU - Yacoub, Abdulraheem

AU - Ghalie, Richard

AU - Giorgino, Ruben

AU - Atallah, Ehab

PY - 2019/2/26

Y1 - 2019/2/26

N2 - Pracinostat, a potent oral pan-histone deacetylase inhibitor with modest single-agent activity in acute myeloid leukemia (AML), has shown synergistic antitumor activity when combined with azacitidine. This single-group, multicenter phase 2 study assessed the safety and efficacy of pracinostat combined with azacitidine in patients who were at least 65 years old with newly diagnosed AML and who were ineligible for standard induction chemotherapy. Patients received pracinostat 60 mg/d, 3 d/wk, for 3 consecutive weeks, plus azacitidine 75 mg/m2 daily for 7 days in a 28-day cycle. Primary endpoints were complete remission (CR), CR with incomplete count recovery (CRi), and morphologic leukemia-free state (MLFS) rates of the combination. Secondary endpoints included safety, progression-free survival (PFS), and overall survival (OS) of the regimen. Fifty patients (33 de novo, 12 secondary, and 5 therapy-related AML) were enrolled. Twenty-six patients (52%) achieved the primary endpoint of CR (42%), CRi (4%), and MLFS (6%). Median OS and PFS were 19.1 months (95% confidence interval [CI], 10-26.5 months) and 12.6 months (95% CI, 10-17.7 months), respectively, with a 1-year OS rate of 62%. Forty-three patients (86%) experienced at least 1 grade 3 or worse treatment-emergent adverse event with the combination, with infections (52%), thrombocytopenia (46%), and febrile neutropenia (44%) reported as the most common toxicities. The 30- and 60-day all-cause mortality rates were 2% and 10%, respectively. DNA sequencing revealed somatic mutations at baseline, and clearance rates correlated with response to treatment. Pracinostat plus azacitidine is a well-tolerated and active regimen in the frontline treatment of older patients with AML unfit for intensive therapy. A larger controlled trial is ongoing. This trial was registered at www.clinicaltrials.gov as #NCT01912274.

AB - Pracinostat, a potent oral pan-histone deacetylase inhibitor with modest single-agent activity in acute myeloid leukemia (AML), has shown synergistic antitumor activity when combined with azacitidine. This single-group, multicenter phase 2 study assessed the safety and efficacy of pracinostat combined with azacitidine in patients who were at least 65 years old with newly diagnosed AML and who were ineligible for standard induction chemotherapy. Patients received pracinostat 60 mg/d, 3 d/wk, for 3 consecutive weeks, plus azacitidine 75 mg/m2 daily for 7 days in a 28-day cycle. Primary endpoints were complete remission (CR), CR with incomplete count recovery (CRi), and morphologic leukemia-free state (MLFS) rates of the combination. Secondary endpoints included safety, progression-free survival (PFS), and overall survival (OS) of the regimen. Fifty patients (33 de novo, 12 secondary, and 5 therapy-related AML) were enrolled. Twenty-six patients (52%) achieved the primary endpoint of CR (42%), CRi (4%), and MLFS (6%). Median OS and PFS were 19.1 months (95% confidence interval [CI], 10-26.5 months) and 12.6 months (95% CI, 10-17.7 months), respectively, with a 1-year OS rate of 62%. Forty-three patients (86%) experienced at least 1 grade 3 or worse treatment-emergent adverse event with the combination, with infections (52%), thrombocytopenia (46%), and febrile neutropenia (44%) reported as the most common toxicities. The 30- and 60-day all-cause mortality rates were 2% and 10%, respectively. DNA sequencing revealed somatic mutations at baseline, and clearance rates correlated with response to treatment. Pracinostat plus azacitidine is a well-tolerated and active regimen in the frontline treatment of older patients with AML unfit for intensive therapy. A larger controlled trial is ongoing. This trial was registered at www.clinicaltrials.gov as #NCT01912274.

UR - http://www.scopus.com/inward/record.url?scp=85061620083&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061620083&partnerID=8YFLogxK

U2 - 10.1182/bloodadvances.2018027409

DO - 10.1182/bloodadvances.2018027409

M3 - Article

VL - 3

SP - 508

EP - 518

JO - Blood advances

JF - Blood advances

SN - 2473-9529

IS - 4

ER -